person · Reporting owner

Carmona Jose

Disclosed activity across 4 companies

Tapewire entity: 32873
SEC CIK: 0001693612

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ADC Therapeutics SAADCT · Entity 6502	Chief Financial Officer	June 30, 2026	July 02, 2026
Innocoll Holdings plcINNL · Entity 12261	CFO	January 01, 2017	January 03, 2017
Radius Health, Inc.RDUS · Entity 124173	Chief Financial Officer	February 26, 2020	February 28, 2020
Rubius Therapeutics, Inc.RUBY · Entity 116417	Chief Financial Officer	January 31, 2022	February 01, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADC Therapeutics SA

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	938,076	Reported balance After 2026-06-30 transaction · row 1 1 source row Row 1 · 2026-06-30 · Grant · Acquired 203,700 · Balance 938,076 F1: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Innocoll Holdings plc

Report date January 01, 2017 · Filed January 03, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative	Direct	240,142	Reported balance Holding disclosure · report date 2017-01-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 240,142 F1: Includes restricted stock units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2025-09-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: These options were granted on September 1, 2015 pursuant to the stock option plan maintained by the Issuer's predecessor, and reissued under the Issuer's 2016 Omnibus Incentive Compensation Plan (the "Plan"), and vest over a 3 year period, with 1/3 vesting on the first anniversary of the grant date, and the remainder vesting quarterly over the following 2 years. Unvested and vested shares underlying the option award are subject to forfeiture, accelerated vesting and other restrictions as more fully set forth in the Plan and each agreement pursuant to which the option award was issued.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-01-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: These options were granted on March 30, 2016, and vest over a 3 year period, with 1/3 vesting on the first anniversary of the grant date, and the remainder vesting quarterly over the following 2 years. Unvested and vested shares underlying the option award are subject to forfeiture, accelerated vesting and other restrictions as more fully set forth in the Plan and each agreement pursuant to which the option award was issued.

Filing footnotes · ownership attribution and instrument terms

F1: Includes restricted stock units.

F2: These options were granted on September 1, 2015 pursuant to the stock option plan maintained by the Issuer's predecessor, and reissued under the Issuer's 2016 Omnibus Incentive Compensation Plan (the "Plan"), and vest over a 3 year period, with 1/3 vesting on the first anniversary of the grant date, and the remainder vesting quarterly over the following 2 years. Unvested and vested shares underlying the option award are subject to forfeiture, accelerated vesting and other restrictions as more fully set forth in the Plan and each agreement pursuant to which the option award was issued.

F3: These options were granted on March 30, 2016, and vest over a 3 year period, with 1/3 vesting on the first anniversary of the grant date, and the remainder vesting quarterly over the following 2 years. Unvested and vested shares underlying the option award are subject to forfeiture, accelerated vesting and other restrictions as more fully set forth in the Plan and each agreement pursuant to which the option award was issued.

Radius Health, Inc.

Report date February 26, 2020 · Filed February 28, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	46,708	Reported balance After 2020-02-26 transaction · row 1 1 source row Row 1 · 2020-02-26 · Sale · Disposed 1,292 · Balance 46,708 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Rubius Therapeutics, Inc.

Report date January 31, 2022 · Filed February 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.75 · Expires 2032-01-30	Direct	143,750	Reported balance After 2022-01-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-01-31 · Grant · Acquired 143,750 · Balance 143,750 F1: 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	34,500	Reported balance After 2022-01-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-01-31 · Grant · Acquired 34,500 · Balance 34,500 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2026 Filed Jul 2, 2026 21:16 UTC	ADC Therapeutics SA ADCT · Entity 6502	GrantCommon Shares	203,700	$0.00	$0.00	Disclosure SEC source: 0001628280-26-047033 · wk-form4_1783026959.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 938,076 F1 · shares: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
February 13, 2026 Filed Feb 18, 2026 22:42 UTC	ADC Therapeutics SA ADCT · Entity 6502	Tax withholdingCommon Shares	25,880	$3.99	$103,261.20	Disclosure SEC source: 0001628280-26-009278 · wk-form4_1771454570.xml · nonDerivative · entry 2 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734,376 F2 · shares: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document
February 13, 2026 Filed Feb 18, 2026 22:42 UTC	ADC Therapeutics SA ADCT · Entity 6502	GrantCommon Shares	271,600	$3.99	$1,083,684.00	Disclosure SEC source: 0001628280-26-009278 · wk-form4_1771454570.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,256 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document
December 06, 2025 Filed Dec 9, 2025 22:09 UTC	ADC Therapeutics SA ADCT · Entity 6502	Tax withholdingCommon Shares	53,236	$3.29	$175,146.44	Disclosure SEC source: 0001628280-25-056168 · wk-form4_1765318145.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,656 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document
February 13, 2025 Filed Feb 14, 2025 23:21 UTC	ADC Therapeutics SA ADCT · Entity 6502	GrantCommon Shares	240,000	$1.61	$386,400.00	Disclosure SEC source: 0001628280-25-005860 · wk-form4_1739575294.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 541,892 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document
December 06, 2024 Filed Dec 10, 2024 01:37 UTC	ADC Therapeutics SA ADCT · Entity 6502	Tax withholdingCommon Shares	48,108	$3.13	$150,578.04	Disclosure SEC source: 0001628280-24-050541 · wk-form4_1733794651.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,892 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document
January 31, 2022 Filed Feb 1, 2022 21:20 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	GrantRestricted Stock Units · Derivative	34,500	$0.00	$0.00	Disclosure SEC source: 0001179110-22-000696 · edgar.xml · derivative · entry 2 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. F3 · derivative.expiration_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. Read SEC document
January 31, 2022 Filed Feb 1, 2022 21:20 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	GrantStock Option (Right to Buy) · Derivative	143,750	$0.00 Strike: $6.75	$0.00	Disclosure SEC source: 0001179110-22-000696 · edgar.xml · derivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,750 Underlying: Common Stock · 143,750 shares Expires 2032-01-30 F1 · derivative.exercise_date: 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter. Read SEC document
November 30, 2020 Filed Dec 2, 2020 06:23 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	GrantStock Option (Right to Buy) · Derivative	400,000	$0.00 Strike: $6.27	$0.00	Disclosure SEC source: 0001179110-20-011522 · edgar.xml · derivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-11-29 F1 · derivative.exercise_date: 25% of this option shall vest on October 1, 2021, then in 12 equal quarterly installments thereafter. Read SEC document
February 26, 2020 Filed Feb 28, 2020 21:15 UTC	Radius Health, Inc. RDUS · Entity 124173	SaleCommon Stock	1,292	$17.93	$23,169.44	Disclosure SEC source: 0001209191-20-013789 · doc4.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,708 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document
February 20, 2020 Filed Feb 24, 2020 22:48 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantStock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $19.96	$0.00	Disclosure SEC source: 0001209191-20-012138 · doc4.xml · derivative · entry 2 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-02-20 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 20, 2021, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. Read SEC document
February 20, 2020 Filed Feb 24, 2020 22:48 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-012138 · doc4.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in three substantially equal annual installments on each of the first three anniversaries of the grant date of February 20, 2020, subject to continued service with RDUS through such dates. Read SEC document
February 22, 2019 Filed Feb 26, 2019 23:21 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantStock Option (Right to Buy) · Derivative	55,000	$0.00 Strike: $19.18	$0.00	Disclosure SEC source: 0001209191-19-013735 · doc4.xml · derivative · entry 2 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-02-22 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. Read SEC document
February 22, 2019 Filed Feb 26, 2019 23:21 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantCommon Stock	15,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-013735 · doc4.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates. Read SEC document
February 13, 2018 Filed Feb 16, 2018 00:34 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $37.83	$0.00	Disclosure SEC source: 0001209191-18-010542 · doc4.xml · derivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-02-12 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document
September 14, 2017 Filed Sep 15, 2017 17:14 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	3,000	$32.83	$98,502.90	Disclosure SEC source: 0001209191-17-052913 · doc4.xml · nonDerivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.8311 to $32.84, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Common Stock purchased at each separate price. Read SEC document
May 15, 2017 Filed May 16, 2017 20:08 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantStock Option (Right to Buy) · Derivative	125,000	$0.00 Strike: $34.96	$0.00	Disclosure SEC source: 0001209191-17-032616 · doc4.xml · derivative · entry 1 Carmona Jose · CIK 0001693612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-05-15 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on May 15, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.